← Leaderboards
Edward A Sausville
Clinical Sciences
$6,399,210
Attributed
$6,927,931
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2006–17$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$6,927,931 · 11
By mechanism
K12$4,016,846 · 1
P30$1,136,729 · 3
R44$1,057,443 · 1
R21$622,500 · 1
M01$94,413 · 5
Top collaborators
- Mylisa Parette1 shared
Most similar at Clinical Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchFundingProgramsUniversitiesMarylandCancer CenterResearch PersonnelBaltimoreClinical TrialsGrantLaboratoriesClinical ProtocolsSourceMedical SchoolsBaseResourcesMedicalDoctor Of PhilosophyPopulation SciencesDoctor Of MedicinePharmaceutical PreparationsMalignant NeoplasmsEducational CurriculumPharmacy Facility
Grant awards (25)
Early Phase Clinical Research Support$139,064
P30 · FY2017 · CA · contact PI
Clinical Protocol and Data Management$124,886
P30 · FY2017 · CA · contact PI
Clinical Protocol and Data Management$125,543
P30 · FY2016 · CA · contact PI
Early Phase Clinical Research Support$125,542
P30 · FY2016 · CA · contact PI
Clinical Investigation of the Ceramide NanoLiposome for Advanced Solid Tumors$1,057,443
R44 · FY2015 · CA
UMGCC Paul Calabresi Clinical Oncology Training Program$826,874
K12 · FY2013 · CA · contact PI
UMGCC Paul Calabresi Clinical Oncology Training Program$1,065,746
K12 · FY2012 · CA · contact PI
UMGCC Paul Calabresi Clinical Oncology Training Program$1
K12 · FY2011 · CA · contact PI
UMGCC Paul Calabresi Clinical Oncology Training Program$1,121,174
K12 · FY2010 · CA · contact PI
Clinical Research Shared Service$242,052
P30 · FY2010 · CA · contact PI
UMGCC Paul Calabresi Clinical Oncology Training Program$708,076
K12 · FY2009 · CA · contact PI
Treatment of Melanoma with wild-type P53 and detectable S100B using pentamidine:$311,250
R21 · FY2009 · CA · contact PI
Clinical Research Shared Service$227,785
P30 · FY2009 · CA · contact PI
CLINICAL TRIAL: TREATMENT OF MELANOMA WITH WILD-TYPE P53 AND A 100B USING PENTA$9,629
M01 · FY2009 · RR · contact PI
Treatment of Melanoma with wild-type P53 and detectable S100B using pentamidine:$311,250
R21 · FY2008 · CA · contact PI
UMGCC Paul Calabresi Clinical Oncology Training Program$294,975
K12 · FY2008 · CA · contact PI
Clinical Research Shared Service$151,857
P30 · FY2008 · CA · contact PI
CLINICAL TRIAL: PHASE I STUDY OF IV 17-AAG AND ORAL BAY 43-9006 IN PATIENTS WITH$20,645
M01 · FY2008 · RR · contact PI
0458GCC: A PHASE I DOSE ESCALATION STUDY OF INTRAVENOUS 17-AAG$40,682
M01 · FY2007 · RR · contact PI
0629GCC: A PHASE I, OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION STUDY TO ASSESS SL$3,156
M01 · FY2007 · RR · contact PI
PHASE 1 OF SORAFENIB PLUS 17AAG IN SOLID TUMOR PATIENTS$20,301
M01 · FY2006 · RR · contact PI
Protein Kinase Antagonists: Preclinical and Clinical$0
Z01 · FY2001 · SC
Immunotoxin Protocols Under the Medicine Branch: Targete$0
Z01 · FY2001 · SC
Immunotoxin Protocols Under the Medicine Branch: Targeted Therapy of Lymphoid Ne$0
Z01 · FY2000 · SC
Protein Kinase Antagonists: Preclinical and Clinical$0
Z01 · FY2000 · SC